世界のリウマチ性腫瘍随伴症候群治療市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV04517)
◆英語タイトル:Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV04517
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:94
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはリウマチ性腫瘍随伴症候群治療の世界市場について調査・分析した資料です。種類別(投薬、理学療法、その他)の市場規模、用途別(病院、診療所、外来外科センター、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別リウマチ性腫瘍随伴症候群治療の競争状況、市場シェア
・世界のリウマチ性腫瘍随伴症候群治療市場:種類別市場規模 2015年-2020年(投薬、理学療法、その他)
・世界のリウマチ性腫瘍随伴症候群治療市場:種類別市場規模予測 2021年-2026年(投薬、理学療法、その他)
・世界のリウマチ性腫瘍随伴症候群治療市場:用途別市場規模 2015年-2020年(病院、診療所、外来外科センター、その他)
・世界のリウマチ性腫瘍随伴症候群治療市場:用途別市場規模予測 2021年-2026年(病院、診療所、外来外科センター、その他)
・北米のリウマチ性腫瘍随伴症候群治療市場分析:米国、カナダ
・ヨーロッパのリウマチ性腫瘍随伴症候群治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのリウマチ性腫瘍随伴症候群治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のリウマチ性腫瘍随伴症候群治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのリウマチ性腫瘍随伴症候群治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Siemens Healthineers、Koninklijke Philips、General Electric、Esaote、NeuroLogica、Masimo、York Instruments、Neusoft Medical Systems、Canon Medical Systems
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically seen in the middle-aged population to older population. This syndrome mostly occurs with patients suffering from lung, ovarian, or breast cancers.

Market Analysis and Insights: Global Rheumatologic Paraneoplastic Syndrome Treatment Market
The global Rheumatologic Paraneoplastic Syndrome Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Rheumatologic Paraneoplastic Syndrome Treatment Scope and Market Size
Rheumatologic Paraneoplastic Syndrome Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Rheumatologic Paraneoplastic Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Siemens Healthineers
Koninklijke Philips
General Electric
Esaote
NeuroLogica
Masimo
York Instruments
Neusoft Medical Systems
Canon Medical Systems

Market segment by Type, the product can be split into
Medication
Physical Therapy
Others
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Rheumatologic Paraneoplastic Syndrome Treatment Revenue
1.4 Market by Type
1.4.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medication
1.4.3 Physical Therapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Perspective (2015-2026)
2.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Growth Trends by Regions
2.2.1 Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Rheumatologic Paraneoplastic Syndrome Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Rheumatologic Paraneoplastic Syndrome Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Rheumatologic Paraneoplastic Syndrome Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Market Size
3.1.1 Global Top Rheumatologic Paraneoplastic Syndrome Treatment Players by Revenue (2015-2020)
3.1.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Concentration Ratio
3.2.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Rheumatologic Paraneoplastic Syndrome Treatment Revenue in 2019
3.3 Rheumatologic Paraneoplastic Syndrome Treatment Key Players Head office and Area Served
3.4 Key Players Rheumatologic Paraneoplastic Syndrome Treatment Product Solution and Service
3.5 Date of Enter into Rheumatologic Paraneoplastic Syndrome Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Historic Market Size by Type (2015-2020)
4.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)
5.2 Global Rheumatologic Paraneoplastic Syndrome Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
6.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in North America (2019-2020)
6.3 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
6.4 North America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
7.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Europe (2019-2020)
7.3 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
7.4 Europe Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

8 China
8.1 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
8.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in China (2019-2020)
8.3 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
8.4 China Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
9.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Japan (2019-2020)
9.3 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
9.4 Japan Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
10.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

11 India
11.1 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
11.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in India (2019-2020)
11.3 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
11.4 India Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size (2015-2020)
12.2 Rheumatologic Paraneoplastic Syndrome Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Type (2015-2020)
12.4 Central & South America Rheumatologic Paraneoplastic Syndrome Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Siemens Healthineers
13.1.1 Siemens Healthineers Company Details
13.1.2 Siemens Healthineers Business Overview
13.1.3 Siemens Healthineers Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.1.4 Siemens Healthineers Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020))
13.1.5 Siemens Healthineers Recent Development
13.2 Koninklijke Philips
13.2.1 Koninklijke Philips Company Details
13.2.2 Koninklijke Philips Business Overview
13.2.3 Koninklijke Philips Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.2.4 Koninklijke Philips Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.2.5 Koninklijke Philips Recent Development
13.3 General Electric
13.3.1 General Electric Company Details
13.3.2 General Electric Business Overview
13.3.3 General Electric Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.3.4 General Electric Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.3.5 General Electric Recent Development
13.4 Esaote
13.4.1 Esaote Company Details
13.4.2 Esaote Business Overview
13.4.3 Esaote Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.4.4 Esaote Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.4.5 Esaote Recent Development
13.5 NeuroLogica
13.5.1 NeuroLogica Company Details
13.5.2 NeuroLogica Business Overview
13.5.3 NeuroLogica Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.5.4 NeuroLogica Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.5.5 NeuroLogica Recent Development
13.6 Masimo
13.6.1 Masimo Company Details
13.6.2 Masimo Business Overview
13.6.3 Masimo Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.6.4 Masimo Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.6.5 Masimo Recent Development
13.7 York Instruments
13.7.1 York Instruments Company Details
13.7.2 York Instruments Business Overview
13.7.3 York Instruments Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.7.4 York Instruments Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.7.5 York Instruments Recent Development
13.8 Neusoft Medical Systems
13.8.1 Neusoft Medical Systems Company Details
13.8.2 Neusoft Medical Systems Business Overview
13.8.3 Neusoft Medical Systems Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.8.4 Neusoft Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.8.5 Neusoft Medical Systems Recent Development
13.9 Canon Medical Systems
13.9.1 Canon Medical Systems Company Details
13.9.2 Canon Medical Systems Business Overview
13.9.3 Canon Medical Systems Rheumatologic Paraneoplastic Syndrome Treatment Introduction
13.9.4 Canon Medical Systems Revenue in Rheumatologic Paraneoplastic Syndrome Treatment Business (2015-2020)
13.9.5 Canon Medical Systems Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Siemens Healthineers、Koninklijke Philips、General Electric、Esaote、NeuroLogica、Masimo、York Instruments、Neusoft Medical Systems、Canon Medical Systems

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のリウマチ性腫瘍随伴症候群治療市場2026:インサイト・予測(Global Rheumatologic Paraneoplastic Syndrome Treatment Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。